ClinicalTrialsFinder
RecruitingNCT05117125

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia

Sponsor

Region Skane

Enrollment

1,000 participants

Start Date

Oct 15, 2021

Study Type

OBSERVATIONAL

Conditions

Pneumonia, Ventilator-Associated

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Admission to an intensive care unit
  • Intubation within last 24 hours
  • Anticipated mechanical ventilation of at least 48 hours

Exclusion Criteria3

  • FiO2 above 70% or PEEP above 15
  • Ongoing infection of the lungs at admission to the ICU.
  • Severely elevated or instable intracranial pressure.
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTHeparin-binding protein

Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTInterleukin-26

Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTMicrobiome

Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

DIAGNOSTIC_TESTBacterial transcriptome

Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

DIAGNOSTIC_TESTProteome

Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Locations(5)

Vestre Viken

Drammen, Norway

Hospital de São Francisco Xavier

Lisbon, Portugal

Skåne University Hospital, Dept. of Infectious diseases

Lund, Sweden

Skåne university Hospital, ICU

Malmo, Sweden

Karolinska University Hospital, ICU

Solna, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05117125

Related Trials

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

NCT058437869 locations

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT070526041 location

Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response

NCT064678641 location

Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

NCT066070551 location

Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia

NCT035279921 location